Eisai slashes forecast as Aricept's plunge drags down first-half figures
This article was originally published in Scrip
Executive Summary
The precipitous plunge in sales of the Alzheimer's disease therapy Aricept (donepezil) following the loss of US exclusivity last November overshadowed Eisai's results for the second quarter, marking a sobering fall for what was the firm's long-time top product.